-
1
Incretin-based therapies, particularly GLP-1 receptor agonists, reduce major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.
-
2
Semaglutide 2.4 mg has shown cardiovascular benefits in individuals with obesity and established cardiovascular disease, independent of diabetes.
-
3
Dual and triple incretin-based agonists, along with combination strategies, are reshaping treatment algorithms for cardiovascular disease.
-
4
The biological mechanisms of GLP-1 receptor activation involve anti-inflammatory and vasodilatory pathways, contributing to cardiovascular protection.
-
5
Current evidence highlights the need for careful interpretation of cardiovascular outcome trials due to variability in study design and patient populations.
